Format

Send to

Choose Destination
Future Microbiol. 2019 Oct;14:1293-1308. doi: 10.2217/fmb-2019-0135. Epub 2019 Oct 1.

Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance.

Author information

1
Department of Surgery, University of Cincinnati College of Medicine, 6005 Given Road Cincinnati, OH 45243, USA.
2
Medical Writing, World Surgical Infection Society, Cincinnati, OH 45243, USA.
3
Medical Affairs, Tetraphase Pharmaceuticals, Watertown, MA 02472, USA.

Abstract

Aim: Recently approved for use in complicated intra-abdominal infection, eravacycline is a novel fluorocycline with broad spectrum of activity against resistant Gram-negative pathogens. This manuscript is a pooled analysis of two Phase III trials. Clinical efficacy: Clinical cure rates were 86.8% for eravacycline versus 87.6% for ertapenem, and 90.8% for eravacycline versus 91.2% for meropenem in the Intent to Treat (micro-ITT) populations, and 87.0% for eravacycline versus 88.8% ertapenem, and 92.4 versus 91.6% for meropenem in the Modified Intent to Treat (MITT) populations. Safety: Eravacycline is well tolerated, with lower rates of nausea, vomiting and diarrhea than other tetracyclines. Conclusion: Eravacycline is an effective new option for use in complicated intra-abdominal infections, and in particular, for the treatment of extended-spectrum β-lactamase- and carbapenem-resistant Enterobacteriaceae-expressing organisms.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01844856 NCT02784704.

KEYWORDS:

CRE; ESBL; Gram-negative; antibiotics; antimicrobial resistance; complicated intra-abdominal infection; eravacycline; tetracycline

PMID:
31570004
DOI:
10.2217/fmb-2019-0135

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center